Expand all sections

Dostarlimab

Extended indication MMRp EC
Therapeutic value No estimate possible yet

Product

Active substance Dostarlimab
Domain Oncology
Reason of inclusion Indication extension
Main indication Oncology other
Extended indication MMRp EC
Manufacturer GSK
Portfolio holder GSK
Budgetting framework Intermural (MSZ)

Registration

Registration route Centralised (EMA)
ATMP No
Submission date May 2024
Expected Registration March 2025
Additional remarks Het voorgenomen label is nog niet bekend.

Therapeutic value

Therapeutic value No estimate possible yet

Expected patient volume per year

There is currently nothing known about the expected patient volume.

Expected cost per patient per year

There is currently nothing known about the expected cost.

Potential total cost per year

There is currently nothing known about the possible total cost.

Off label use

There is currently nothing known about off label use.

Indication extension

There is currently nothing known about indication extensions.

Other information

There is currently no futher information available.